Medovate’s recent e-ESRA congress symposium ‘Mitigating for Nerve Injury by Innovation’ was a reminder that both improvements in patient safety and total cost optimisation are important considerations when introducing new technology to regional anaesthesia (RA).
A collaborative approach involving Medovate and the inventors of ‘SAFIRA®: SAFer Injection for Regional Anaesthesia’, clinicians from the National Health Service (NHS) has resulted in a device that is now available across Europe, the United States and beyond that does both.
During the 4th e-ESRA online conference in March 2021 Medovate sponsored a webinar presented by members of the SAFIRA® clinical inventor team including, Dr Peter Young, Dr Robin Heij, Dr Maria Paz Sebastian and chaired by Dr Ben Fox. The symposium looked at nerve damage in the context of regional anaesthesia and discussed the ways that SAFIRA® could help reduce the risks associated with RA nerve damage during injection. Feedback on its easy assimilation into hospital protocols was also shared with the audience of over 360 anaesthetists from across Europe and beyond.
Sales and Marketing Director at Medovate, Chris Rogers has taken a look at the key symposium takeaways which can be found in the free document download here.